What oligometastatic disease is — and why the definition matters
Stereotactic body radiation therapy (SBRT, or SABR) has stopped being purely palliative in one specific subgroup of metastatic patients: those with few lesions, biologically indolent disease and a controlled primary. In that setting, treating every metastasis to an ablative dose extends progression-free survival and, in at least one randomized trial, overall survival. The topic sits high on ASTRO’s agenda and absorbs a large share of current radiation oncology research.
The concept dates to 1995, when Hellman and Weichselbaum proposed an intermediate state between localized disease and widespread dissemination. In that state the number of metastases is limited and the capacity to seed new lesions is not yet fully established. If the hypothesis holds, eliminating existing foci may alter the natural history of the disease rather than merely relieve symptoms.
The working definition is pragmatic: one to five metastatic lesions, all amenable to ablative treatment, with the primary tumor controlled. It is not a magic number — it is the window in which the trials were designed.
The ESTRO/EORTC nomenclature: not all oligometastases are alike
In 2020 an ESTRO/EORTC consensus produced a vocabulary now mandatory in any serious discussion of the topic. The classification separates genuine oligometastatic disease — appearing while the patient is not on active systemic therapy — from induced disease, revealed when systemic treatment has shrunk tumor burden to a few residual foci.
Within those categories, three terms matter in daily practice:
- Oligorecurrence — a few new lesions emerging off active systemic therapy.
- Oligoprogression — most disease remains controlled by systemic therapy while a small number of lesions escape. This is focal clonal resistance.
- Oligopersistence — a few residual lesions that have not disappeared but are not progressing under treatment.
The distinction is not academic. In oligoprogression, SBRT aims to rescue the current systemic line by removing the resistant clone and postponing a regimen switch. In oligorecurrence, the goal may be to delay starting systemic therapy altogether. Different indications, different endpoints.
The randomized evidence: what SABR-COMET actually showed
SABR-COMET is the reference trial. This phase II study randomized 99 patients with a controlled primary and one to five metastases between standard care alone and standard care plus SABR to all lesions.
Its extended analysis, published with eight years of follow-up, is the longest randomized dataset available in this population. Eight-year overall survival was 27.2% in the SABR arm versus 13.6% in the control arm, and progression-free survival was 21.3% versus 0%. Roughly one in five SABR patients passed five years with no recurrence or progression — which, in some histologies, functionally approaches cure. No control-arm patient survived beyond five years without progression or death.
The curves also plateaued between years four and eight, supporting a reading of durable control rather than mere delay. No new toxicity signal emerged with longer follow-up.
The other side deserves saying. Grade 2 or higher toxicity was clearly more frequent in the SABR arm, and the trial recorded treatment-related deaths. This is not a cost-free procedure, and patient selection is what separates benefit from harm. Phase III confirmation is underway in SABR-COMET-3, for one to three lesions, and SABR-COMET-10, for four to ten.
Oligoprogression: the CURB trial and the limits of benefit
In the oligoprogressive setting, the CURB trial is the most cited randomized evidence. This phase II study enrolled patients with breast cancer or non-small cell lung cancer showing up to five progressing lesions after at least one line of systemic therapy, comparing continued standard care against adding SBRT to the escaping lesions.
Median progression-free survival was 7.2 months with SBRT versus 3.2 months with standard care. The decisive finding, though, is in the histology analysis: the benefit concentrated in non-small cell lung cancer, with more than a fourfold increase in median progression-free survival, while there was no benefit in oligoprogressive breast cancer.
That negative result is as informative as the positive one. It suggests disease biology — not lesion count alone — determines who benefits from local ablation. Extending the oligometastatic concept indiscriminately across histologies is, today, a conceptual error.
What the guidelines say
The joint ASTRO/ESTRO guideline for oligometastatic non-small cell lung cancer conditionally recommends adding definitive local therapy to standard systemic therapy in carefully selected patients — spanning synchronous oligometastatic disease, metachronous oligorecurrence, induced oligopersistence and induced oligoprogression in extracranial disease.
The word “conditional” carries weight. It means the benefit-risk balance is case-dependent and the decision belongs to a multidisciplinary discussion, not an automatic algorithm. The guideline also addresses adequate staging, dose, planning and delivery technique — acknowledging that outcome depends as much on execution as on indication.
Technical requirements: SBRT does not forgive imprecision
Delivering 45 to 60 Gy in three to five fractions means working with very steep dose gradients. A geometric error of a few millimeters stops being irrelevant: it can underdose the target or fully irradiate an adjacent critical organ. That is why SBRT is inseparable from daily image guidance, rigid immobilization and respiratory motion management — whether via 4D-CT, abdominal compression, breath-hold or real-time tracking.
Schedules are compared through biologically effective dose, which adjusts physical dose for fraction size:
$$\mathrm{BED} = n\,d\left(1 + \frac{d}{\alpha/\beta}\right)$$
where $n$ is the number of fractions, $d$ is dose per fraction and $\alpha/\beta$ is the tissue radiosensitivity parameter — typically 10 Gy for tumors. This is why 54 Gy in three fractions carries a far higher BED than conventional schedules: local control in lung lesions improves consistently above roughly 100 Gy BED.
There are well-established caution zones too. Central and especially ultracentral thoracic lesions — near the proximal bronchial tree, esophagus and great vessels — require more protracted fractionation and strict dose constraints. The same technical discipline drives progress in ablative radiotherapy for pancreatic cancer, where duodenal proximity imposes an identical dosimetric problem.
Selection, alternatives and what comes next
In practice, the factors weighing most in favor of ablation are a controlled primary, a low lesion count, a long interval between primary treatment and metastatic appearance, good performance status and favorable histology. Metachronous disease with a long disease-free interval behaves better than high-volume synchronous disease.
SBRT is not the only ablation route. Radiofrequency, microwave and cryoablation, metastasectomy and intra-arterial therapies compete and complement depending on site. Systemic targeted radiation is also reshaping the field — the scramble for radioligand supply visible in the Curium–Lantheus deal reflects exactly this shift toward dose delivered by biology rather than geometry.
One methodological caveat is rarely mentioned: better imaging changes the definition itself. PSMA PET, high-resolution FDG PET/CT and whole-body MRI detect lesions older exams missed. That shifts patients between staging categories and artificially inflates historical results through stage migration. Comparing series from different eras demands care — a shift already visible in how MRI is taking over local staging in prostate cancer.
Access is the other constraint. SBRT requires an accelerator with image guidance, an adequate planning system, dedicated medical physics and a quality assurance program — a combination that is not universally available. Looking ahead, phase III results from SABR-COMET-3 and SABR-COMET-10 should settle whether the phase II benefit holds and how many lesions are worth treating. Until then, the defensible approach is what the guidelines already describe: rigorous selection, multidisciplinary discussion and flawless technical execution.
Sources: ASTRO — Clinical Practice Guidelines and the ASTRO/ESTRO guideline on oligometastatic non-small cell lung cancer (Practical Radiation Oncology).
